Group items tagged

Phase I clinical trial of i.v. ascorbic acid in advanced malignancy. Hoffer LJ, Levine M, Assouline S, Melnychuk D, Padayatty SJ, Rosadiuk K, Rousseau C, Robitaille L, Miller WH Jr. Ann Oncol. 2008 Nov;19(11):1969-74. Epub 2008 Jun 9. Erratum in: Ann Oncol. 2008 Dec;19(12):2095. PMID: 18544557 doi:10.1093/annonc/mdn377

Multi-targeted therapy of cancer by omega-3 fatty acids. Berquin IM, Edwards IJ, Chen YQ. Cancer Lett. 2008 Oct 8;269(2):363-77. Epub 2008 May 13. Review. PMID: 18479809 doi:10.1016/j.canlet.2008.03.044

Relationship between low ultraviolet B irradiance and higher breast cancer risk in 107 countries. Mohr SB, Garland CF, Gorham ED, Grant WB, Garland FC. Breast J. 2008 May-Jun;14(3):255-60. Epub 2008 Apr 17. PMID: 18422861 DOI: 10.1111/j.1524-4741.2008.00571.x There was a protective effect of UVB irradiance on risk of breast cancer that was independent of fertility rate, proportion of the population overweight, alcohol intake, animal energy intake, and other covariates.

The controversial place of vitamin C in cancer treatment. Verrax J, Calderon PB. Biochem Pharmacol. 2008 Dec 15;76(12):1644-52. Epub 2008 Sep 30. Review. PMID: 18938145 doi:10.1016/j.bcp.2008.09.024    

Dichloroacetate induces apoptosis in endometrial cancer cells. Wong JY, Huggins GS, Debidda M, Munshi NC, De Vivo I. Gynecol Oncol. 2008 Jun;109(3):394-402. Epub 2008 Apr 18. PMID: 18423823 doi:10.1016/j.ygyno.2008.01.038

Apoptotic effects of dietary and synthetic sphingolipids in androgen-independent (PC-3) prostate cancer cells. Kent KD, Clubbs EA, Harper WJ, Bomser JA. Lipids. 2008 Feb;43(2):143-9. Epub 2008 Jan 10. PMID: 18188632 DOI: 10.1007/s11745-007-3148-

Structure-function relationships of anthocyanins from various anthocyanin-rich extracts on the inhibition of colon cancer cell growth. Jing P, Bomser JA, Schwartz SJ, He J, Magnuson BA, Giusti MM. J Agric Food Chem. 2008 Oct 22;56(20):9391-8. Epub 2008 Sep 19. PMID: 18800807 DOI: 10.1021/jf8005917

Multiple roles for CD4+ T cells in anti-tumor immune responses. Kennedy R, Celis E. Immunol Rev. 2008 Apr;222:129-44. Review. PMID: 18363998 DOI: 10.1111/j.1600-065X.2008.00616.x

Nutrient intake and immune function of elderly subjects. Wardwell L, Chapman-Novakofski K, Herrel S, Woods J. J Am Diet Assoc. 2008 Dec;108(12):2005-12. PMID: 19027403 doi:10.1016/j.jada.2008.09.003

Anticancer properties of oxidation products of docosahexaenoic acid. Siddiqui RA, Harvey K, Stillwell W. Chem Phys Lipids. 2008 May;153(1):47-56. Epub 2008 Feb 23. Review. PMID: 18343223

Bioavailability and Kinetics of Sulforaphane in Humans after Consumption of Cooked versus Raw Broccoli Martijn Vermeulen*, Ineke W. A. A. Klpping-Ketelaars†, Robin van den Berg‡ and Wouter H. J. Vaes J. Agric. Food Chem., 2008, 56 (22), pp 10505-10509 Publication Date (Web): October 24, 2008 (Article) DOI: 10.1021/jf801989e

Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. Attard G, Reid AH, Yap TA, Raynaud F, Dowsett M, Settatree S, Barrett M, Parker C, Martins V, Folkerd E, Clark J, Cooper CS, Kaye SB, Dearnaley D, Lee G, de Bono JS. J Clin Oncol. 2008 Oct 1;26(28):4563-71. Epub 2008 Jul 21. PMID: 18645193 DOI: 10.1200/JCO.2007.15.9749

Combination of an EGFR blocker and a COX-2 inhibitor for the treatment of advanced cutaneous squamous cell carcinoma. Jalili A, Pinc A, Pieczkowski F, Karlhofer FM, Stingl G, Wagner SN. J Dtsch Dermatol Ges. 2008 Dec;6(12):1066-9. English, German. PMID: 19138272 DOI: 10.1111/j.1610-0387.2008.06861.x

Vitamin C and cancer revisited. Frei B, Lawson S. Proc Natl Acad Sci U S A. 2008 Aug 12;105(32):11037-8. Epub 2008 Aug 5. PMID: 18682554

Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. Chen Q, Espey MG, Sun AY, Pooput C, Kirk KL, Krishna MC, Khosh DB, Drisko J, Levine M. Proc Natl Acad Sci U S A. 2008 Aug 12;105(32):11105-9. Epub 2008 Aug 4. PMID: 18678913 doi: 10.1073/pnas.0804226105

Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer.\nMichelakis ED, Webster L, Mackey JR.\nBr J Cancer. 2008 Oct 7;99(7):989-94. Epub 2008 Sep 2. Review.\nPMID: 18766181 \ndoi:10.1038/sj.bjc.6604554 \n

Addressing the health benefits and risks, involving vitamin D or skin cancer, of increased sun exposure.\nMoan J, Porojnicu AC, Dahlback A, Setlow RB.\nProc Natl Acad Sci U S A. 2008 Jan 15;105(2):668-73. Epub 2008 Jan 7.\nPMID: 18180454

Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer. Michelakis ED, Webster L, Mackey JR. Br J Cancer. 2008 Oct 7;99(7):989-94. Epub 2008 Sep 2. Review. PMID: 18766181 doi:10.1038/sj.bjc.6604554 The unique metabolism of most solid tumours (aerobic glycolysis, i.e., Warburg effect) is not only the basis of diagnosing cancer with metabolic imaging but might also be associated with the resistance to apoptosis that characterises cancer. The glycolytic phenotype in cancer appears to be the common denominator of diverse molecular abnormalities in cancer and may be associated with a (potentially reversible) suppression of mitochondrial function. The generic drug dichloroacetate is an orally available small molecule that, by inhibiting the pyruvate dehydrogenase kinase, increases the flux of pyruvate into the mitochondria, promoting glucose oxidation over glycolysis. This reverses the suppressed mitochondrial apoptosis in cancer and results in suppression of tumour growth in vitro and in vivo. Here, we review the scientific and clinical rationale supporting the rapid translation of this promising metabolic modulator in early-phase cancer clinical trials More than 40 nonrandomised trials of DCA in small cohorts of patients have been reported, but the first two randomised control trials of chronic oral therapy with DCA in congenital mitochondrial diseases were reported in 2006. In the first, a blinded placebo-controlled study was performed with oral DCA administered at 25 mg kg-1 day-1 in 30 patients with MELAS syndrome (mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes) (Kaufmann et al, 2006). Most patients enrolled in the DCA arm developed symptomatic peripheral neuropathy, compared with 4 out of 15 in the placebo arm, leading to the termination of the study. Seventeen out of 19 patients had at least partial resolution of peripheral neurological symptoms by 9 months after discontinuation of DCA. This neurotoxicity res

Is regular exercise a friend or foe of the aging immune system? A systematic review. Haaland DA, Sabljic TF, Baribeau DA, Mukovozov IM, Hart LE. Clin J Sport Med. 2008 Nov;18(6):539-48. Review. PMID: 19001887 doi: 10.1097/JSM.0b013e3181865eec

Opposing effects of n-6 and n-3 polyunsaturated fatty acids on pancreatic cancer growth. Funahashi H, Satake M, Hasan S, Sawai H, Newman RA, Reber HA, Hines OJ, Eibl G. Pancreas. 2008 May;36(4):353-62. PMID: 18437081 doi: 10.1097/MPA.0b013e31815ccc44